Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023

Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) is set to host a live webcast and conference call on May 3, 2023, at 8:30 a.m. ET to discuss its first quarter 2023 financial results and provide business updates. Analysts can participate in the Q&A session via an audio conferencing link. The archived version of the webcast will later be available on the company's website. Wave Life Sciences is focused on developing genetic medicines for severe diseases using its proprietary PRISM platform, which aims to create high-quality stereopure oligonucleotides. This initiative reflects the company's commitment to improving patient outcomes for genetically defined diseases.

Positive

• Upcoming webcast to review Q1 2023 financial results.
• Focus on genetic medicines development with proprietary PRISM platform.

Negative

• None.

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, May 3, 2023, to review the company’s first quarter 2023 financial results and provide business updates.

The webcast and conference call may be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: ir.wavelifesciences.com/events-and-presentations.

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
InvestorRelations@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com

FAQ

What are Wave Life Sciences' financial results for Q1 2023?

The financial results for Q1 2023 will be discussed during the webcast scheduled for May 3, 2023.

When is the Wave Life Sciences conference call?

The conference call will be held on May 3, 2023, at 8:30 a.m. ET.

How can I access the Wave Life Sciences Q1 2023 webcast?

You can access the webcast by visiting the 'Investor Events' section on the Wave Life Sciences website.

What is the purpose of Wave Life Sciences' upcoming webcast?

The webcast aims to review the company's Q1 2023 financial results and provide business updates.

What platform does Wave Life Sciences use for drug development?

Wave Life Sciences employs its proprietary PRISM platform for drug discovery and development.